Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Dalila Salvatore,
Myriam Labopin,
Annalisa Ruggeri,
Giorgia Battipaglia,
Ardeshir Ghavamzadeh,
Fabio Ciceri,
Didier Blaise,
William Arcese,
Gerard Sociè,
Jean Henri Bourhis,
Maria Teresa Van Lint,
Benedetto Bruno,
Anne Huynh,
Stella Santarone,
Eric Deconinck,
Mohamad Mohty,
Arnon Nagler
Affiliations
Dalila Salvatore
Service d’Hématologie et Thérapie Cellulaire Hôpital Saint Antoine, Paris, France;Hematology Department, Federico II University, Naples, Italy
Myriam Labopin
Service d’Hématologie et Thérapie Cellulaire Hôpital Saint Antoine, Paris, France;Hospital Saint-Antoine, Paris University UPMC, France;Acute Leukemia Working Party of EBMT, Paris, France
Annalisa Ruggeri
Service d’Hématologie et Thérapie Cellulaire Hôpital Saint Antoine, Paris, France;Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children’s Hospital, Roma, Italy
Giorgia Battipaglia
Service d’Hématologie et Thérapie Cellulaire Hôpital Saint Antoine, Paris, France;Hematology Department, Federico II University, Naples, Italy
Ardeshir Ghavamzadeh
Shariati Hospital, Hematology-Oncology and BMT Research, Teheran, Iran
Fabio Ciceri
Haematology and BMT Unit, IRCCS Ospedale San Raffaele, Milano, Italy
Didier Blaise
Programme de Transplantation &Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, France
William Arcese
Stem Cell Transplant Unit, Policlinico Universitario Tor Vergata, Rome, Italy
Gerard Sociè
Hopital St. Louis, Dept.of Hematology – BMT, Paris, France
Jean Henri Bourhis
Hematology department, Institut Gustave Roussy, Villejuif, France
Maria Teresa Van Lint
Ospedale San Martino, Department of Haematology II Genova
Benedetto Bruno
A.O.U. Città della Salute e della Scienza, Torino, Italy
Anne Huynh
Institut Universitaire du Cancer Toulouse, Oncopole, France
Stella Santarone
Unità Terapia Intensiva Ematologica per il Trapianto Emopoietico, Ospedale Civile, Pescara, Italia
Eric Deconinck
Hopital Jean Minjoz, Service d’Hématologie, Besançon, France
Mohamad Mohty
Service d’Hématologie et Thérapie Cellulaire Hôpital Saint Antoine, Paris, France;Hospital Saint-Antoine, Paris University UPMC, France;Acute Leukemia Working Party of EBMT, Paris, France
Arnon Nagler
Acute Leukemia Working Party of EBMT, Paris, France;Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate - acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option. We compared outcomes of unmanipulated (Haplo) to matched sibling donor transplant in acute myeloid leukemia patients in first complete remission. Included were intermediate and high-risk acute myeloid leukemia in first complete remission undergoing Haplo and matched sibling donor transplant from 2007–2015, and reported to the ALWP of the EBMT. A propensity score technique was used to confirm results of main analysis: 2 matched sibling donors were matched with 1 Haplo. We identified 2654 pts (Haplo =185; matched sibling donor =2469), 2010 with intermediate acute myeloid leukemia (Haplo=122; matched sibling donor =1888) and 644 with high-risk acute myeloid leukemia (Haplo =63; matched sibling donor =581). Median follow up was 30 (range 1–116) months. In multivariate analysis, in intermediate - acute myeloid leukemia patients, Haplo resulted in lower leukemia-free survival (Hazard Ratio 1.74; P
